(19)
(11) EP 3 107 548 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.07.2022 Bulletin 2022/29

(45) Mention of the grant of the patent:
08.06.2022 Bulletin 2022/23

(21) Application number: 15752250.9

(22) Date of filing: 20.02.2015
(51) International Patent Classification (IPC): 
A61K 31/616(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/616; A61K 9/0075; A61K 31/4365; A61P 9/10
(86) International application number:
PCT/US2015/016969
(87) International publication number:
WO 2015/127315 (27.08.2015 Gazette 2015/34)

(54)

DRY POWDER FORMULATIONS FOR INHALATION

TROCKENPULVERFORMULIERUNGEN ZUR INHALATION

PRÉPARATIONS DE POUDRE SÈCHE À INHALER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 20.02.2014 US 201461942545 P
31.07.2014 US 201462031811 P

(43) Date of publication of application:
28.12.2016 Bulletin 2016/52

(60) Divisional application:
22176400.4

(73) Proprietor: Otitopic Inc.
New York, NY 10017 (US)

(72) Inventor:
  • YADIDI, Kambiz
    Westlake Village, California 91361 (US)

(74) Representative: Ellis, Robin Patrick 
Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street
London E1 8QS
London E1 8QS (GB)


(56) References cited: : 
US-A1- 2008 044 481
US-A1- 2010 258 118
US-B2- 6 979 437
 US-A1- 2008 306 033
US-A1- 2014 322 328
   
  • HADINOTO ET AL: "Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 341, no. 1-2, 24 July 2007 (2007-07-24), pages 195-206, XP022166304, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2007.03.035
  • H.J.M. BARNETT; M. KASTE; H.MELDRUM; M. ELIASZIW: "Aspirin dose in stroke prevention", STROKE, vol. 27, 31 December 1996 (1996-12-31), pages 588-592,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).